Meeting Details - The fifth meeting of the Supervisory Board of Beijing Saiseng Pharmaceutical Co., Ltd. was held on June 19, 2025, with all three attending supervisors present [1][2] - The meeting was legally convened in accordance with relevant laws and regulations [1] Resolutions Passed - The Supervisory Board approved the proposal regarding the signing of a "New Drug Technology Transfer Contract" and related transactions [1][2] - The board confirmed that the transaction is necessary for the company's normal operations and aligns with its development strategy [2] Compliance and Impact - The Supervisory Board concluded that the transaction complies with legal and regulatory requirements and does not affect the company's independence or harm the interests of shareholders, particularly minority shareholders [2]

Core Viewpoint - The company has signed a new drug technology transfer contract with its affiliate, with a total transaction amount of 20 million yuan [1] Group 1: Transaction Details - The company has entered into a technology transfer agreement for the NeoAB33 new drug project with its affiliate, Huada Protein, for a total of 20 million yuan [1] - The transaction is classified as a related party transaction due to the involvement of the company's chairman, general manager, and chief engineer in Huada Protein's management [1] Group 2: Strategic Implications - The acquisition of the relevant technology will accelerate the development of the company's protein/antibody drug platform, enhancing its capabilities from molecular design to cell line construction [1] - The company aims to expand its pipeline reserves in the cardiovascular field, promoting a differentiated competitive layout in this niche market and accelerating the transformation of research and development results [1]

证券代码：300485 证券简称：赛升药业 公告编码：2025-025 北京赛升药业股份有限公司 关于签订《新药技术转让合同》暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 基于业务发展需要，北京赛升药业股份有限公司（以下简称"公司"或 "甲方"）与参股公司北京华大蛋白质研发中心有限公司（以下简称"华大蛋 白"或"乙方"）签署《新药技术转让合同》，华大蛋白将其拥有的NeoAB33新 药项目相关技术转让给公司，交易总额为2,000万元。 鉴于公司持有华大蛋白27.89%股权，公司董事长兼总经理马骉先生担任华 大蛋白的董事，公司总工程师孔双泉先生担任华大蛋白的董事，公司董事尹长 城先生担任华大蛋白董事兼总经理，根据《深圳证券交易所创业板股票上市规 则》，本次公司与华大蛋白签订《新药技术转让合同》构成关联交易。 公司于 2025 年 6 月 19 日召开了第五届董事会第八次会议及第五届监事会 第八次会议，审议通过了《关于签订<新药技术转让合同>暨关联交易的议案》。 董事会上，关联董事马骉、马丽、尹长城回避表决，全体独立董事表决同意 ...

证券代码：300485 证券简称：赛升药业 公告编号：2025-024 北京赛升药业股份有限公司 第五届监事会第八次会议决议公告 三、备查文件 第五届监事会第八次会议决议 北京赛升药业股份有限公司（以下简称"公司"）第五届监事会第八次会议 于 2025 年 6 月 19 日在公司会议室召开，本次会议于 2025 年 6 月 13 日以通讯的 方式向所有监事送达了会议通知。会议应参会监事 3 人，实际参会监事 3 人，公 司董事会秘书列席会议。会议由监事会主席赵丽娜女士主持。本次会议的召开符 合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，会议决议合法、有效。 二、会议审议情况 经全体监事认真审议并表决，会议通过了以下议案： 审议通过《关于签订〈新药技术转让合同〉暨关联交易的议案》 本议案具体内容详见发布于中国证监会指定的创业板信息披露网站的《关于 签订<新药技术转让合同>暨关联交易的公告》。 经审核，监事会认为：本次关联交易系公司正常经营需要，符合公司发展战 略，决策程序符合相关法律、法规及公司章程的规定，不会对公司的独立性造成 影响，不存在损害公司及股东利益，特别是中 ...

证券代码：300485 证券简称：赛升药业 公告编号：2025-023 北京赛升药业股份有限公司 第五届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第八次会议 于2025年6月19日在公司会议室召开，本次会议于2025年6月13日以通讯的方式向 所有董事送达了会议通知。会议应参会董事8人，实际参会董事8人，会议由董事 长马骉先生主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符 合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 审议通过《关于签订〈新药技术转让合同〉暨关联交易的议案》 本议案具体内容详见发布于中国证监会指定的创业板信息披露网站的《关于 签订<新药技术转让合同>暨关联交易的公告》。 特此公告。 北京赛升药业股份有限公司 董 事 会 2025 年 6 月 20 日 公司独立董事专门会议审议通过了本议案。 表决结果 ...

Core Viewpoint - The company has signed a technology transfer agreement with its affiliate, BGI Protein, for the NeoAB33 new drug project, with a total transaction amount of 20 million yuan, which constitutes a related party transaction [1] Group 1: Transaction Details - The transaction involves the transfer of detailed technical materials, technical details, and related documents for the NeoAB33 project, including constructed cell lines and related research, characterization analysis, preliminary pharmaceutical and immunological studies, initial process research, and preliminary quality research technical materials, along with all original records in both written and electronic formats [1] - The agreement is based on an assessment result, ensuring that the pricing is fair and reasonable after sufficient communication between the parties involved [1] Group 2: Strategic Implications - This transaction will help the company accelerate the construction of its protein/antibody drug platform, expand its pipeline reserves in the cardiovascular field, and promote differentiated competitive layout in this niche market [1] - The agreement is expected to facilitate the transformation of research and development results, achieve technological complementarity and resource integration, and support the improvement of the company's innovative drug research and development system and market competitiveness [1]

智通财经6月19日电，早盘创新药概念延续调整，常山药业触及20CM跌停，翰宇药业跌超10%，通化金 马、广生堂、赛升药业、舒泰神等跟跌。 创新药概念延续调整 常山药业触及跌停 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry, indicating that the industry index is expected to outperform the benchmark index by more than 10% [7][24]. Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.40% from June 9 to June 13, 2025, outperforming the CSI 300 by 1.65 percentage points [2][12]. - Year-to-date, the Shenwan Pharmaceutical Bio Index has increased by 9.33%, surpassing the CSI 300 by 11.13 percentage points, ranking 4th among 31 Shenwan primary industry indices [2][14]. - As of June 13, 2025, the valuation of the pharmaceutical sector stands at 28.29 times (TTM overall method, excluding negative values), with a valuation premium of 153.19% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector has outperformed the CSI 300 index, ranking 5th among 31 primary industry indices during the specified period [2][12]. - The sector's valuation reflects a significant premium over the broader market, indicating strong investor interest [2][17]. 2. Important Events - On June 13, 2025, a State Council meeting emphasized the need for enhanced evaluation of drug and consumable procurement policies, aiming for a more standardized and institutionalized approach to procurement [4][21]. - The meeting also highlighted the importance of improving public hospital compensation mechanisms and supporting pharmaceutical companies in enhancing innovation capabilities [4][21]. 3. Industry Perspective - The report notes that the procurement process in China's pharmaceutical sector has been ongoing for nearly a decade, expanding from solid oral formulations to include various drug categories and medical devices [5][22]. - There is a positive outlook for innovative drugs, overseas expansion, and sectors where procurement impacts have been cleared, suggesting potential growth opportunities [5][22]. - The report encourages attention to specific segments such as insulin and orthopedics, as well as certain generic drug companies, due to the ongoing acceleration of procurement processes [5][22].

A股创新药板块走势分化，赛升药业涨超11%，千红制药涨超8%，百洋医药、悦康药业均涨超7%；荣 昌生物跌超7%，润都股份跌超6%，热景生物跌超5%。 订阅A股市场资讯 +订阅 ...

Group 1 - The innovation drug sector is currently experiencing significant attention and growth, with a warning against chasing high-priced stocks like Lianhua Technology and Shutaishen, which have seen substantial price increases [1][5] - 2023 has been a year of explosive new drug approvals, with a notable event on May 29 when the National Medical Products Administration issued 11 new drug approvals, with five coming from innovative drug companies on the Sci-Tech Innovation Board [3][4] - The innovation drug sector has shown a continuous growth trend for seven weeks, breaking through the historical resistance level of 1180 points, indicating strong upward momentum and potential [5] Group 2 - Investors are advised to focus on small-cap stocks that are severely undervalued and possess core technologies, as larger companies with market caps in the hundreds of billions may offer limited profit potential [7] - Notable small-cap stocks include: - Saiseng Pharmaceutical, with a market cap of approximately 6.5 billion yuan, focusing on nerve repair and immune regulation, with a key product being the first domestic nerve glycoside approved for clinical efficacy [9] - Anglikang, with a market cap of around 5.2 billion yuan, transitioning towards tumor microenvironment activation therapies, with several innovative drugs in clinical trials [10] - A third company, referred to as an "invisible king," is developing a long-acting therapeutic vaccine for cardiovascular treatment, with a market cap of less than 3 billion yuan and significant interest from foreign investment firms [11]